ABLI — Abliva AB Share News
0.000.00%
Last trade - 00:00- SEK467.94m
- SEK435.27m
Brief: Neurovive Pharmaceutical Q3 Pre-Tax Loss Widens To SEK 15 Million
Brief: Neurovive Pharmaceutical AB Q3 Pre-Tax Loss Sek 15 Million Versus Loss Sek 13.2 Million Year Ago
Brief: NeuroVive Receives Vinnova Funding
Brief: Neurovive Receives Kl1333 Clinical Trial Regulatory Approval
Brief: Neurovive Gets Positive FDA Feedback On Neurostat TBI Development Plan
Brief: Neurovive: Research Partner Gets Three-Year Grant
Brief: Neurovive Pharmaceutical Q2 Loss Before Tax Widens To SEK 25.5 Mln
Brief: NeuroCive Out-Licenses Targeted Lhon Therapy To Bridgebio Pharma
Swedish stocks: Seen opening slightly higher
Brief: NeuroVive Pharmaceutical Q1 Pre-Tax Loss Narrows To SEK 13.1 Million
Brief: NeuroVive And Yungjin Report Positive KL1333 Phase I Clinical Study Results
Brief: NeuroVive Initiates Collaboration With US TBI Research Organization
Brief: NeuroVive Raises About SEK 78.5 Million In Rights Issue
Brief: NeuroVive Receives FDA Orphan Drug Designation
Brief: Neurovive Pharmaceutical Q4 Pre-Tax Loss Widens To SEK 14.8 Mln
Brief: Neurovive Decides On A Rights Issue For Continued Drug Development
Brief: NeuroVive Program Granted ODD By The European Commission
Brief: NeuroVive Reports Progress In Clinical Project KL1333
Brief: NeuroVive Pharmaceuticals Amends Number Of Shares And Votes